Monica Cabrero Calvo-rekin lankidetzan egindako argitalpenak (11)
2024
-
Ofatumumab as part of reduced intensity conditioning in high risk B-cell lymphoma patients: final long-term analysis from a prospective multicenter Phase-II Trial
Bone Marrow Transplantation
-
Treatment of post-allogeneic hematopoietic stem cell transplant cytopenias with sequential doses of multipotent mesenchymal stromal/stem cells
Cytotherapy
2022
-
ABCL-297 Hemophagocytic Lymphohistiocytosis Singularity: A Multicenter Retrospective Study
Clinical Lymphoma, Myeloma and Leukemia, Vol. 22, pp. S369-S370
-
CT-169 Cytokine Release Syndrome After Peripheral Blood Haploidentical Stem Cell Transplantation With Post-Transplant Cyclophosphamide: Time of Onset Matters
Clinical Lymphoma, Myeloma and Leukemia, Vol. 22, pp. S437-S438
2021
-
Allogeneic stem cell transplantation as a curative option in relapse/refractory diffuse large B cell lymphoma: Spanish multicenter GETH/GELTAMO study
Bone Marrow Transplantation, Vol. 56, Núm. 8, pp. 1919-1928
2020
-
Measures to Maintain a SARS-CoV-2 Negative Inpatient Hematological Unit in the Midst of the COVID-19 Pandemic
Frontiers in Medicine, Vol. 7
2019
-
Usefulness of eltrombopag for treating thrombocytopenia after allogeneic stem cell transplantation
Bone Marrow Transplantation
2016
-
Fludarabine/Busulfan versus Fludarabine/Melphalan Conditioning in Patients Undergoing Reduced-Intensity Conditioning Hematopoietic Stem Cell Transplantation for Lymphoma
Biology of Blood and Marrow Transplantation, Vol. 22, Núm. 10, pp. 1808-1815
2015
-
Influence of donor age in allogeneic stem cell transplant outcome in acute myeloid leukemia and myelodisplastic syndrome
Leukemia Research, Vol. 39, Núm. 8, pp. 828-834
2014
-
Risk factors for thrombotic microangiopathy in allogeneic hematopoietic stem cell recipients receiving GVHD prophylaxis with tacrolimus plus MTX or sirolimus
Bone Marrow Transplantation, Vol. 49, Núm. 5, pp. 684-690